Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...
The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...
As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
Eli Lilly ( LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the ...
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...
A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...
Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of ...
The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.
The prevalence of type 2 diabetes is rising globally, with a disproportionate impact on individuals in low-income and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results